Influence of Chocolate With Plant Additives on Episodic Memory in Healthy Subjects Experiencing Test Anxiety

NCT ID: NCT03382067

Last Updated: 2018-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-04

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, blind parallel group design. Single intake of 55 g high Epicatechin /Melissa dark chocolate containing 160 mg Epicatechin per 55 g serving or single intake of 55 g low Epicatechin/ oat bran white chocolate containing \< 0,00045 mg Epicatechin per 55 g serving.

A Total of 128 participants, 64 in each group, approx. equal number of male and female. There will be replacement of Drop-Outs until data from 128 participants are completed.

The primary endpoints will be performance in a pictorial memory task and a verbal memory task .

The secondary endpoints will be performance in a working memory test, Saliva cortisol, Visual analog scales assessing, anxiety, confidence, interference, solicitude, and excitement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Test Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Epicatechin/ Melissa

Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves

Group Type ACTIVE_COMPARATOR

High Epicatechin/ Melissa

Intervention Type DIETARY_SUPPLEMENT

Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa

Low Epicatechin/ Oat bran

Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing \< 0,0009 mg (-)-Epicatechin/100g

Group Type PLACEBO_COMPARATOR

Low Epicatechin/ Oat bran

Intervention Type OTHER

Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Epicatechin/ Melissa

Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa

Intervention Type DIETARY_SUPPLEMENT

Low Epicatechin/ Oat bran

Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy by history
* normotensive (BP between 90/60 mmHg and 140/90 mmHg)
* BMI between 18 and \< 30 kg/m2
* male or female
* aged between 18 and 30 years
* native or fluent German-speaking
* Prüfungsangstfragebogen (PAF) total or subscale interference score T value \> 60

Exclusion Criteria

* Known hypersensitivity or allergy to cocoa, Melissa, oat, vanillin, milk, soja, nuts
* gluten intolerance
* lactose intolerance
* acute or chronic psychiatric disorder including drug or alcohol abuse
* women who are pregnant or breast feeding
* any clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease etc., infections)
* known or suspected non-compliance
* smoking (\> 5 cigarettes per day)
* participation in one of our previous studies using the same memory tests in the past 2 years
* participation in a study with investigational drug within the 30 days preceding and during the present study
* long-term medication within last 3 months (oral contraceptives are disregarded)
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Prof. Dominique de Quervain, MD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Dominique de Quervain, MD

Prof. Dominique de Quervain, MD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dominique DeQuervain, Prof. MD

Role: PRINCIPAL_INVESTIGATOR

University Basel Divison of Cognitive Neuroscience

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Basel, Division of Cognitive Neuroscience

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MaRS-Basel

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacological Cognitive Enhancement
NCT01684306 COMPLETED EARLY_PHASE1